Protein expression profiling in the spectrum of renal cell carcinomas

Journal of Cancer

Volumn 1, Issue 1, 2010, Pages 184-196

  Valera, Vladimir A ^a   Li Ning T, Elsa ^a   Walter, Beatriz A ^a   Roberts, David D ^a   Linehan, W M ^a   Merino, Maria J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biomarker; Hsp27; Protein profiling; Proteomics; Renal cell carcinoma; TPI 1

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA ENOLASE; APOLIPOPROTEIN A1; BETA GLOBIN; COPPER ZINC SUPEROXIDE DISMUTASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FERRITIN; FERRITIN LIGHT POLYPEPTIDE; HAPTOGLOBIN; HEAT SHOCK PROTEIN 27; PEROXIREDOXIN 2; RAD23B PROTEIN; TRIOSEPHOSPHATE ISOMERASE; TRIOSEPHOSPHATE ISOMERASE 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CHROMOPHOBE ADENOMA; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MALE; MASS SPECTROMETRY; ONCOCYTOMA; PAPILLARY CARCINOMA; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

EID: 78650108812     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.1.184     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Reuter V, Tickoo SK. Adult Renal Tumors. In: Sternberg SS, Mills SE, Carter D, eds. Sternberg's diagnostic surgical pathology, 4th edn. Philadelphia: Lippincott Williams & Wilkins. 2004: 2710-2775.
3. Grignon DJ. Kidney Tumors in Adults. In: Murphy WM, Grignon DJ, Perlman EJ, eds. Tumors of the kidney, bladder, and related urinary structures; AFIP atlas of tumor pathology; Fourth series. Washington DC: American Registry of Pathology. 2004: 394.
4. Grignon D. Pathology of Kidney Tumors. In: Mydlo JH, ed. Renal cancer: methods and protocols. Totowa, N.J.: Humana Press. 2001: 35-51.
5. Linehan WM, Vasselli J, Srinivasan R, et al. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004; 10:6282S-6289S.
6. Pavlovich CP, Schmidt LS, Phillips JL. The genetic basis of renal cell carcinoma. Urol Clin North Am 2003; 30:437-454.
7. Langner C, Ratschek M, Rehak P, Schips L, Zigeuner R. CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology 2004; 45:460-467.
8. Liao SY, Aurelio ON, Jan K, Zavada J, Stanbridge EJ. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997; 57:2827-2831.
9. Perroud B, Lee J, Valkova N, et al. Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 2006; 5:64.
10. th edn. Lyon: IARC Press, Oxford University Press. 2004: 12-14.
11. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC cancer staging manual, 6th edn. New York: Springer. 2002.
12. Walter BA, Valera VA, Takahashi S, Matsuno K, Ushiki T. Evidence of antibody production in the rat cervical lymph nodes after antigen administration into the cerebrospinal fluid. Arch Histol Cytol 2006; 69:37-47.
13. Sarto C, Deon C, Doro G, et al. Contribution of proteomics to the molecular analysis of renal cell carcinoma with an emphasis on manganese superoxide dismutase. Proteomics 2001; 1:1288-1294.
14. Sarto C, Valsecchi C, Magni F, et al. Expression of heat shock protein 27 in human renal cell carcinoma. Proteomics 2004; 4:2252-2260.
15. Sarto C, Marocchi A, Sanchez JC, et al. Renal cell carcinoma and normal kidney protein expression. Electrophoresis 1997; 18:599-604.
16. Balabanov S, Zimmermann U, Protzel C, et al. Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem 2001; 268:5977-5980.
17. Lichtenfels R, Kellner R, Bukur J, et al. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2002; 2:561-570.
18. Arthur JM, Thongboonkerd V, Scherzer JA, et al. Differential expression of proteins in renal cortex and medulla: a proteomic approach. Kidney Int 2002; 62:1314-1321.
19. Banks RE, Craven RA, Harnden P, et al. Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007; 25:537-556.
20. Seliger B, Lichtenfels R, Atkins D, et al. Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma. Proteomics 2005; 5:2631-2640.
21. Zhuang Z, Huang S, Kowalak JA, et al. From tissue phenotype to proteotype: sensitive protein identification in microdissected tumor tissue. Int J Oncol 2006; 28:103-110.
22. Unwin RD, Craven RA, Harnden P, et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics 2003; 3:1620-1632.
23. Khan W, McGuirt JP, Sens MA, Sens DA, Todd JH. Expression of heat shock protein 27 in developing and adult human kidney. Toxicol Lett 1996; 84:69-79.
24. Erkizan O, Kirkali G, Yorukoglu K, Kirkali Z. Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology 2004; 64:474-478.
25. Tremolada L, Magni F, Valsecchi C, et al. Characterization of heat shock protein 27 phosphorylation sites in renal cell carcinoma. Proteomics 2005; 5:788-795.
26. Fanelli MA, Cuello Carrion FD, Dekker J, Schoemaker J, Ciocca DR. Serological detection of heat shock protein hsp27 in normal and breast cancer patients. Cancer Epidemiol Biomarkers Prev 1998; 7:791-795.
27. Joo M, Chi JG, Lee H. Expressions of HSP70 and HSP27 in hepatocellular carcinoma. J Korean Med Sci 2005; 20:829-834.
28. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995; 1:1603-1609.
29. Madersbacher S, Grobl M, Kramer G, et al. Regulation of heat shock protein 27 expression of prostatic cells in response to heat treatment. Prostate 1998; 37:174-181.
30. Kamada M, So A, Muramaki M, et al. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007; 6:299-308.
31. Sarto C, Binz PA, Mocarelli P. Heat shock proteins in human cancer. Electrophoresis 2000; 21:1218-1226.
32. Manjili MH, Wang XY, Park J, et al. Immunotherapy of cancer using heat shock proteins. Front Biosci 2002; 7:d43-52.
33. Lavoie JN, Lambert H, Hickey E, Weber LA, Landry J. Modulation of cellular thermoresistance and actin filament stability accompanies phosphorylation-induced changes in the oligomeric structure of heat shock protein 27. Mol Cell Biol 1995; 15:505-516.
34. Keezer SM, Ivie SE, Krutzsch HC, et al. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regula tion of heat shock protein 27 and cofilin. Cancer Res 2003; 63:6405-6412.
35. Isenberg JS, Jia Y, Field L, et al. Modulation of angiogenesis by dithiolethione-modified NSAIDs and valproic acid. Br J Pharmacol 2007; 151:63-72.
36. Robert J, Van Rymenant M, Lagae F. Enzymes in cancer. III. Triosephosphate isomerase activity of human blood serum in normal individuals and in individuals with various pathological conditions. Cancer 1961; 14:1166-1174.
37. Zhang D, Tai LK, Wong LL, et al. Proteomic Study Reveals That Proteins Involved in Metabolic and Detoxification Pathways Are Highly Expressed in HER-2/neu-positive Breast Cancer. Mol Cell Proteomics 2005; 4:1686-1696.